Ublituximab Shows Benefit Among Patients With Relapsing Multiple Sclerosis
Using data from the Ultimate I and II phase 3 trials, researchers conducted a post-hoc analysis to study the effects of ublituximab on disease activity in relapsing multiple sclerosis.